Loading
companiesCompany
Biocon
India's largest biopharmaceutical company, founded by Kiran Mazumdar-Shaw in 1978, and the parent of Biocon Biologics, which makes low-cost copies of the antibodies trastuzumab and bevacizumab.
Overview
Biocon was founded in Bengaluru in 1978 by Kiran Mazumdar-Shaw and grew from enzymes into generic active ingredients, insulins and antibodies. Its oncology footprint runs through Biocon Biologics (biosimilars) and Syngene (contract research). Biocon launched ALZUMAb (itolizumab, an anti-CD6 antibody) for psoriasis in 2013 and CANMAb, a trastuzumab biosimilar, in India in 2014 after CDSCO approval; Roche contested the approval and the litigation ended in 2016. With Mylan (now Viatris) it took the same molecule to the US as Ogivri, approved in December 2017, the first trastuzumab biosimilar approved by the FDA, and to the EU in December 2018. Biocon also sells a bevacizumab biosimilar in India (Krabeva) and, as Abevmy, in the EU (April 2021).
Headquarters
Bengaluru, IN
Scorecard
All companies#60of 1244 companies, score 66
- approved products +18
- targets +6
- modalities +2
- regions +8
- 24-month regulatory events +2
- registry trials +30
3 approved, 0 in phase 3, 0 earlier, 3 targets, 3,827 registry studies. Formula on the scorecards page.
Type
Large pharma · BIOCON.NS
Stage
Public
Website
Founded
1978
ApprovedBiosimilar monoclonal antibody (anti-HER2)
Trastuzumab biosimilars · Ogivri, Herzuma, Kanjinti, Trazimera, Ontruzant, Hercessi
Near-identical copies of Herceptin, approved since 2017, that cut the price of HER2 treatment and widened access worldwide.
ApprovedMonoclonal antibody (anti-HER2)
Trastuzumab · Herceptin (and biosimilars, Phesgo with pertuzumab)
The first targeted antibody for a solid tumour (1998), which turned HER2-positive breast cancer from the worst subtype into one of the most treatable.
ApprovedMonoclonal antibody (anti-VEGF)
Bevacizumab · Avastin (and biosimilars)
Bevacizumab is a humanised antibody that soaks up VEGF-A, the signal tumours use to grow new blood vessels. Approved in 2004, it partners chemotherapy in colorectal, ovarian, cervical, lung, kidney and liver cancer and glioblastoma, and adds to trifluridine/tipiracil in late-line bowel cancer; hypertension, protein in the urine and bleeding are its characteristic side effects.
EstablishedHumanised anti-EGFR monoclonal antibody, intravenous
Nimotuzumab · BIOMAb EGFR / TheraCIM / CIMAher
Nimotuzumab is a Cuban-developed antibody against EGFR approved in India, China, Cuba and other countries for head and neck cancer, nasopharyngeal cancer and brain tumours, usually with radiotherapy; it causes far less rash than cetuximab but has never been approved in the United States or Europe.
Similar pages
- IdeaMake the biosimilar the default at the pharmacy for trastuzumab, bevacizumab and rituximab
Shares Trastuzumab biosimilars, Biosimilar, Prices and value, Trastuzumab.
- CompanyViatris
Shares Biocon Biologics, Trastuzumab biosimilars, Biosimilar manufacturing and comparability, Biosimilar.
- CompanyHetero Drugs
Shares Biosimilar, Prices and value, Bevacizumab, Most of the world has almost no cancer care.
- IdeaWHO prequalification plus pooled demand to push biosimilar prices below 10% of the originator
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Trastuzumab, Most of the world has almost no cancer care.
- CompanyDr. Reddy's Laboratories
Shares Biosimilar manufacturing and comparability, Biosimilar, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value.
- TermBiologics Price Competition and Innovation Act 2010
Shares Trastuzumab biosimilars, Biosimilar, Prices and value, Trastuzumab.
- IdeaTie WHO essential-medicines listing to a published tiered price and supply pledge
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Trastuzumab, Most of the world has almost no cancer care.
- IdeaBiosimilar-first defaults and payment parity in every cancer day unit
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Trastuzumab, Monoclonal antibodies.
fronts
technologies
drugs
ApprovedMonoclonal antibody (anti-VEGF)
Bevacizumab · Avastin (and biosimilars)
EstablishedHumanised anti-EGFR monoclonal antibody, intravenous
Nimotuzumab · BIOMAb EGFR / TheraCIM / CIMAher
ApprovedMonoclonal antibody (anti-HER2)
Trastuzumab · Herceptin (and biosimilars, Phesgo with pertuzumab)
ApprovedBiosimilar monoclonal antibody (anti-HER2)
Trastuzumab biosimilars · Ogivri, Herzuma, Kanjinti, Trazimera, Ontruzant, Hercessi